![]() | |
![]() | |
Clinical data | |
---|---|
Other names | 12-Methoxyibogamine |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.363 |
Chemical and physical data | |
Formula | C20H26N2O |
Molar mass | 310.441 g·mol−1 |
3D model (JSmol) | |
Melting point | 152 to 153 °C (306 to 307 °F) |
| |
| |
(verify) |
Ibogaine is an psychoactive indole alkaloid obtained either by extraction from plants in the family Apocynaceae such as Tabernanthe iboga, Voacanga africana, and Tabernaemontana undulata or by semi-synthesis from the precursor compound voacangine, another plant alkaloid. The total synthesis of ibogaine was described in 1956.[3] Structural elucidation by X-ray crystallography was completed in 1960.[4][5][6]
The psychoactivity of the root bark of the iboga tree, Tabernanthe iboga, one of the plants from which ibogaine is extracted, was first discovered by the Pygmy tribes of Central Africa, who passed the knowledge to the Bwiti tribe of Gabon. French explorers in turn learned of it from the Bwiti tribe and brought ibogaine back to Europe in 1899–1900, where it was subsequently marketed in France as a stimulant under the trade name Lambarène. Although ibogaine's anti-addictive properties were first widely promoted in 1962 by Howard Lotsof, its Western medical use predates that by at least a century.
During an eighteen-year timeline, a total of 19 fatalities temporally associated with the ingestion of ibogaine were reported, from which six subjects died of acute heart failure or cardiopulmonary arrest. Its prohibition in many countries has slowed scientific research.[7] Various derivatives of ibogaine designed to lack psychedelic properties, such as 18-MC, are under preliminary research.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search